Biocon Ltd reported a consolidated net sales growth of 19.64%

recently achieved a milestone with the US FDA approval for its subsidiary's diabetes drug, Kristy, a rapid-acting human insulin analog. The company reported a consolidated net sales growth of 19.64% year-on-year to Rs 4,296 crore in Q2 FY26, but experienced a significant net profit decline of 628% compared to the previous year's quarter, mainly due to one-time gains in the base quarter. Despite profitability pressures, Biocon's operating profit margin improved slightly to 19.60%, and cash reserves hit a record high of Rs 4,601 crore.